Factor V Leiden Thrombophilia

Factor V Leiden thrombophilia at a glance

  • Factor V Leiden is a specific inherited change in the F5 gene that increases the tendency to form venous blood clots.
  • Many people with the variant never develop a clot. Risk depends on whether one or two copies are present and on other genetic, medical, hormonal, and temporary risk factors.
  • A positive genetic result does not automatically mean lifelong blood-thinning medicine is needed. Testing and prevention decisions should change care, not simply label risk.
  • Sudden shortness of breath, chest pain, coughing blood, fainting, or one-sided leg swelling and pain needs urgent assessment for a possible clot.
An adult patient and clinician review generic laboratory trends together in a clinic.
Laboratory results need to be interpreted with symptoms, history, examination, and the purpose of the test.

Blood clot warning signs

Seek emergency help for sudden shortness of breath, chest pain that may worsen with a breath, coughing blood, fainting, a very fast heartbeat, or severe unexplained weakness. These can occur with a pulmonary embolism, in which a clot blocks blood flow in the lungs. A pulmonary embolism can be life-threatening and cannot be ruled out at home.

Prompt same-day assessment is important for new swelling, pain, warmth, redness, or discoloration in one leg or arm, especially after surgery, injury, prolonged immobility, pregnancy, childbirth, or estrogen exposure. Those symptoms can have other causes, but a deep vein thrombosis requires imaging and clinical evaluation. This page explains inherited risk and does not replace the separate evaluation and treatment of an actual DVT or pulmonary embolism.

What Factor V Leiden is

Blood clotting protects the body after an injury. Clotting proteins activate in a controlled sequence and are then slowed down so a clot does not keep growing. Factor V is one of these proteins. Activated protein C normally helps switch factor V off.

Factor V Leiden is a particular variant in the F5 gene. The altered factor V protein resists normal inactivation by activated protein C, so clotting activity can persist longer. This creates thrombophilia, meaning a greater tendency to develop an abnormal clot. Factor V Leiden is not factor V deficiency. Factor V deficiency is a different, uncommon bleeding disorder.

The main clinical concern is venous thromboembolism, which includes DVT and pulmonary embolism. Factor V Leiden is a risk factor, not a clot itself. Many carriers remain healthy throughout life. It is not an explanation for every pain, headache, pregnancy complication, or arterial event.

One copy, two copies, and variable risk

A person may inherit one Factor V Leiden copy and one usual F5 copy, called heterozygosity, or inherit the variant from both parents, called homozygosity. Having two copies generally carries a higher clot risk than having one. Risk also differs substantially among people with the same genetic result.

Family history matters, as do age, a previous clot, another thrombophilia, cancer, surgery, major injury, a central venous catheter, prolonged immobility, pregnancy and the postpartum period, obesity, and estrogen-containing contraception or hormone therapy. Long travel may add risk when movement is limited, particularly when other factors are present.

Risk is not a simple percentage that applies to every person. Estimates depend on population, age, study design, one versus two copies, and other exposures. A clinician can place a result in context rather than treating the genetic finding as destiny.

Symptoms and what a carrier may notice

The variant itself generally causes no day-to-day symptoms. Symptoms appear if a clot develops. A DVT can cause one-sided swelling, pain or tenderness, warmth, and skin color change, but some DVTs produce limited symptoms. A pulmonary embolism can cause breathlessness, chest pain, rapid heartbeat, coughing blood, lightheadedness, or collapse.

Clots can occur in less common venous locations, including vessels involving the abdomen, brain, or upper limb. Symptoms depend on location and require specialist evaluation. Common symptoms such as headache or abdominal pain are not evidence of Factor V Leiden thrombosis on their own.

Pregnancy already changes clotting risk, and the postpartum period is especially important. Factor V Leiden can add to risk, but most carriers do not experience a clot and many pregnancies are uncomplicated. A genetic result should not be used alone to predict pregnancy outcome or to start medicine without obstetric and hematology review.

When testing may or may not help

Factor V Leiden can be identified by molecular testing for the specific F5 variant. Some laboratories also use a functional activated protein C resistance test, followed by genetic confirmation when appropriate. Test choice and timing can be affected by anticoagulant medicines, pregnancy, acute illness, or other laboratory factors.

Testing is not automatically useful for every person with a clot or every relative of a carrier. The American Society of Hematology guideline emphasizes that thrombophilia testing should be targeted to situations in which the result is likely to change an important management decision. It recommends against screening the general population before combined oral contraception and makes conditional recommendations for selected clinical and family-history situations.

Before testing, useful questions include: What decision will this result change? Could the test be misleading at this time? What are the possible insurance, privacy, family, or emotional implications? Would a negative result change prevention advice when strong temporary risk factors remain? Genetic counseling can help when family testing or reproductive questions are involved.

A positive result should state whether one or two copies were found and use standard variant terminology. It may prompt review of personal clot history, family history, other risk factors, and possible additional testing. It does not prove that a previous symptom was a clot.

Management after a clot

An acute DVT or pulmonary embolism is treated according to the clot’s location, severity, provoking factors, bleeding risk, kidney and liver function, pregnancy status, and other clinical details. The Factor V Leiden result is one part of that assessment. This page does not choose a blood thinner, dose, or treatment duration.

How long anticoagulation continues depends mainly on why the clot occurred, recurrence risk, and bleeding risk. A person with a clot after a major temporary trigger may have a different plan from someone with an unprovoked or recurrent event. Having one Factor V Leiden copy does not by itself settle the duration decision.

People taking anticoagulants need instructions about missed doses, bleeding, procedures, pregnancy planning, medicine interactions, and which injuries require assessment. Never stop an anticoagulant because a genetic result seems low risk, and do not begin aspirin or a blood thinner solely from an online risk estimate.

Prevention when no clot has occurred

Long-term preventive anticoagulation is not routinely recommended for every asymptomatic person with one Factor V Leiden copy. The potential reduction in clot risk must be balanced against bleeding. Short-term prevention may be considered in selected high-risk situations, but it requires an individualized plan.

Tell clinicians about the result before major surgery, prolonged immobilization, pregnancy, postpartum care, or consideration of estrogen-containing medication. This allows risk to be assessed with all other factors. It does not mean that every procedure, trip, or pregnancy requires injections or another blood thinner.

General measures include moving as soon as safely possible after illness or surgery, following procedure-specific prevention instructions, staying reasonably active, and avoiding smoking. During travel, movement and hydration may support comfort, but they cannot replace prescribed prevention for a high-risk person. Compression garments and medicines should be used only when appropriate for the individual.

Hormones, pregnancy, and family questions

Combined estrogen-containing contraception and oral menopausal hormone therapy can raise venous clot risk. A Factor V Leiden result can change the balance of options, especially with a personal or strong family history. Non-estrogen and non-oral choices have different profiles. Decisions should include the reason for therapy, alternatives, pregnancy goals, and other risk factors.

Pregnancy and postpartum planning may involve obstetrics, maternal-fetal medicine, hematology, and anesthesia. The plan depends on prior clots, one or two variant copies, family history, delivery considerations, and additional risks. Routine testing or routine medication for every relative is not supported by a single universal rule.

Because the variant is inherited, relatives may ask about testing. The most helpful approach starts with whether a result would alter contraception, pregnancy, surgery, or clot-prevention decisions. Testing children or people without a management question deserves careful discussion rather than automatic screening.

Preparing for care

Bring the exact laboratory report, not only a note saying “positive.” Record any prior clot, its location, date, trigger, treatment, and recurrence. Include family clot history with ages and circumstances, pregnancy history, planned procedures, travel, cancer treatment, hormone use, smoking, weight-related risks, and all medicines and supplements.

Ask whether the result is heterozygous or homozygous, what decision it changes, and whether another test is needed. Clarify prevention for surgery, hospitalization, pregnancy, postpartum recovery, and hormone treatment. If anticoagulation is proposed, ask about the reason, expected duration, bleeding signs, interactions, and procedure planning. Request a written emergency plan for possible DVT or pulmonary embolism symptoms.

Official sources